Pharmaceutical attention in the treatment of obesity involving analogues of Glucagon-like peptide 1 (GPL-1)
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/30134 |
Resumo: | The general objective of this article is to explore the knowledge about injectable pharmacological therapy in obesity, while it intends to raise the available evidence regarding the benefits, side effects, and the probable off-label use, involving the Glucagon-like peptide analogues. 1 (GLP-1) used in this treatment. This is an exploratory, integrative literature review study on the impact of pharmaceutical care on injecting drug use in the treatment of obesity. The search for studies was carried out in the electronic databases: NCBI/PubMed, Google Scholar, SciELO and Lilacs - Bireme. The inclusion criteria were: articles available in full, in Portuguese and English, from 2015 to 2022 with free access and that had an affinity with the theme. A total of 40 publications were identified, after applying the inclusion criteria, 24 studies remained. In the selected articles, we identified that GLP-1 receptor agonist drugs have been developed, with mimetic action to the endogenous peptide, prescribed for the treatment of obesity. Liraglutide (Saxenda® and Victoza®) and Semaglutide (Ozempic®), both synthetic GLP-1 incretin analogues, proportionally increase glucose-dependent insulin secretion, reduce glucagon secretion, delay gastric emptying, and decrease appetite, with agonist action on its receptors, resulting in weight loss. In this context, the pharmacist's performance aimed at patients suffering from obesity disorder includes, in addition to evaluating the treatment and guiding the patient, to promote and introduce healthy lifestyle habits. |
id |
UNIFEI_da97aa9b04e052e503c4f4a70ee68540 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/30134 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Pharmaceutical attention in the treatment of obesity involving analogues of Glucagon-like peptide 1 (GPL-1)Atención farmacéutica en el tratamiento de la obesidad con análogos del péptido similar al glucagón 1 (GPL-1)Atenção farmacêutica no tratamento da obesidade envolvendo os análogos do Glucagon-like peptide 1 (GPL-1)LiraglutideSemaglutidePharmaceutical care.LiraglutidaSemaglutidaAtención farmacéutica.LiraglutidaSemaglutidaAtenção farmacêutica.The general objective of this article is to explore the knowledge about injectable pharmacological therapy in obesity, while it intends to raise the available evidence regarding the benefits, side effects, and the probable off-label use, involving the Glucagon-like peptide analogues. 1 (GLP-1) used in this treatment. This is an exploratory, integrative literature review study on the impact of pharmaceutical care on injecting drug use in the treatment of obesity. The search for studies was carried out in the electronic databases: NCBI/PubMed, Google Scholar, SciELO and Lilacs - Bireme. The inclusion criteria were: articles available in full, in Portuguese and English, from 2015 to 2022 with free access and that had an affinity with the theme. A total of 40 publications were identified, after applying the inclusion criteria, 24 studies remained. In the selected articles, we identified that GLP-1 receptor agonist drugs have been developed, with mimetic action to the endogenous peptide, prescribed for the treatment of obesity. Liraglutide (Saxenda® and Victoza®) and Semaglutide (Ozempic®), both synthetic GLP-1 incretin analogues, proportionally increase glucose-dependent insulin secretion, reduce glucagon secretion, delay gastric emptying, and decrease appetite, with agonist action on its receptors, resulting in weight loss. In this context, the pharmacist's performance aimed at patients suffering from obesity disorder includes, in addition to evaluating the treatment and guiding the patient, to promote and introduce healthy lifestyle habits.El objetivo general de este artículo es explorar el conocimiento sobre la terapia farmacológica inyectable en la obesidad, al mismo tiempo que pretende aumentar la evidencia disponible sobre los beneficios, efectos secundarios y probable uso off-label de los análogos de péptidos similares al glucagón1. (GLP-1) utilizado en este tratamiento. Este es un estudio exploratorio e integrador de revisión de la literatura sobre el impacto de la atención farmacéutica en el uso de drogas inyectables en el tratamiento de la obesidad. La búsqueda de estudios se realizó en las bases de datos electrónicas: NCBI/PubMed, Google Scholar, SciELO y Lilacs - Bireme. Los criterios de inclusión fueron: artículos disponibles en su totalidad, en portugués e inglés, de 2015 a 2022 con acceso gratuito y que tuvieran afinidad con el tema. Se identificaron un total de 40 publicaciones, luego de aplicar los criterios de inclusión quedaron 24 estudios. En los artículos seleccionados identificamos que se han desarrollado fármacos agonistas del receptor GLP-1, con acción mimética al péptido endógeno, prescritos para el tratamiento de la obesidad. La liraglutida (Saxenda® y Victoza®) y la semaglutida (Ozempic®), ambos análogos sintéticos de la incretina GLP-1, aumentan proporcionalmente la secreción de insulina dependiente de la glucosa, reducen la secreción de glucagón, retrasan el vaciado gástrico y disminuyen el apetito, con acción agonista sobre sus receptores, lo que resulta en la pérdida de peso. En este contexto, la actuación del farmacéutico dirigida a los pacientes que padecen el trastorno de la obesidad incluye, además de evaluar el tratamiento y orientar al paciente, la promoción e introducción de hábitos de vida saludables.Esse artigo tem como objetivo geral explorar o conhecimento acerca da terapia farmacológica injetável na obesidade, ao passo que se pretende levantar sobre as evidências disponíveis a respeito dos benefícios, efeitos colaterais, e o provável uso off label, envolvendo os análogos do Glucagon-like peptide 1 (GLP-1) utilizados nesse tratamento. Este é um estudo exploratório do tipo revisão de literatura integrativa sobre o impacto da atenção farmacêutica sobre o uso de drogas injetáveis no tratamento da obesidade. A busca de estudos realizou-se nas bases de dados eletrônicas: NCBI/PubMed, Google Scholar, SciELO e Lilacs - Bireme. Os critérios de inclusão foram: artigos disponíveis na integra, em português e inglês, no período de 2015 a 2022 com acesso gratuito e que tivessem afinidade com a temática. Identificaram-se no total 40 publicações, após aplicação dos critérios de inclusão, permaneceram 24 estudos. Nos artigos selecionados, identificamos que vem sido desenvolvidos fármacos agonistas dos receptores GLP-1, com atuação mimética ao peptídeo endógeno, prescrita para o tratamento da obesidade. A Liraglutida (Saxenda® e Victoza®) e a Semaglutida (Ozempic®), ambas análogas sintéticas da incretina GLP-1, aumentam proporcionalmente a secreção de insulina dependente de glicose, reduzem a secreção de glucagon, retarda o esvaziamento gástrico e diminui o apetite, com atuação agonista sobre seus receptores, ocorrendo a perda de peso. Nesse contexto, atuação do farmacêutico voltada a pacientes que sofrem do distúrbio da obesidade compreende, além de avaliar o tratamento e orientar o paciente, em promover e introduzir hábitos de vida saudáveis.Research, Society and Development2022-05-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3013410.33448/rsd-v11i7.30134Research, Society and Development; Vol. 11 No. 7; e41011730134Research, Society and Development; Vol. 11 Núm. 7; e41011730134Research, Society and Development; v. 11 n. 7; e410117301342525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/30134/26001Copyright (c) 2022 Ana Maria Santos Barbosa; Fabrine Rodrigues da Silva Reis; Carolinne Oliveira Marquezhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessBarbosa, Ana Maria Santos Reis, Fabrine Rodrigues da Silva Marquez, Carolinne Oliveira 2022-06-06T15:12:05Zoai:ojs.pkp.sfu.ca:article/30134Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:47:00.118163Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Pharmaceutical attention in the treatment of obesity involving analogues of Glucagon-like peptide 1 (GPL-1) Atención farmacéutica en el tratamiento de la obesidad con análogos del péptido similar al glucagón 1 (GPL-1) Atenção farmacêutica no tratamento da obesidade envolvendo os análogos do Glucagon-like peptide 1 (GPL-1) |
title |
Pharmaceutical attention in the treatment of obesity involving analogues of Glucagon-like peptide 1 (GPL-1) |
spellingShingle |
Pharmaceutical attention in the treatment of obesity involving analogues of Glucagon-like peptide 1 (GPL-1) Barbosa, Ana Maria Santos Liraglutide Semaglutide Pharmaceutical care. Liraglutida Semaglutida Atención farmacéutica. Liraglutida Semaglutida Atenção farmacêutica. |
title_short |
Pharmaceutical attention in the treatment of obesity involving analogues of Glucagon-like peptide 1 (GPL-1) |
title_full |
Pharmaceutical attention in the treatment of obesity involving analogues of Glucagon-like peptide 1 (GPL-1) |
title_fullStr |
Pharmaceutical attention in the treatment of obesity involving analogues of Glucagon-like peptide 1 (GPL-1) |
title_full_unstemmed |
Pharmaceutical attention in the treatment of obesity involving analogues of Glucagon-like peptide 1 (GPL-1) |
title_sort |
Pharmaceutical attention in the treatment of obesity involving analogues of Glucagon-like peptide 1 (GPL-1) |
author |
Barbosa, Ana Maria Santos |
author_facet |
Barbosa, Ana Maria Santos Reis, Fabrine Rodrigues da Silva Marquez, Carolinne Oliveira |
author_role |
author |
author2 |
Reis, Fabrine Rodrigues da Silva Marquez, Carolinne Oliveira |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Barbosa, Ana Maria Santos Reis, Fabrine Rodrigues da Silva Marquez, Carolinne Oliveira |
dc.subject.por.fl_str_mv |
Liraglutide Semaglutide Pharmaceutical care. Liraglutida Semaglutida Atención farmacéutica. Liraglutida Semaglutida Atenção farmacêutica. |
topic |
Liraglutide Semaglutide Pharmaceutical care. Liraglutida Semaglutida Atención farmacéutica. Liraglutida Semaglutida Atenção farmacêutica. |
description |
The general objective of this article is to explore the knowledge about injectable pharmacological therapy in obesity, while it intends to raise the available evidence regarding the benefits, side effects, and the probable off-label use, involving the Glucagon-like peptide analogues. 1 (GLP-1) used in this treatment. This is an exploratory, integrative literature review study on the impact of pharmaceutical care on injecting drug use in the treatment of obesity. The search for studies was carried out in the electronic databases: NCBI/PubMed, Google Scholar, SciELO and Lilacs - Bireme. The inclusion criteria were: articles available in full, in Portuguese and English, from 2015 to 2022 with free access and that had an affinity with the theme. A total of 40 publications were identified, after applying the inclusion criteria, 24 studies remained. In the selected articles, we identified that GLP-1 receptor agonist drugs have been developed, with mimetic action to the endogenous peptide, prescribed for the treatment of obesity. Liraglutide (Saxenda® and Victoza®) and Semaglutide (Ozempic®), both synthetic GLP-1 incretin analogues, proportionally increase glucose-dependent insulin secretion, reduce glucagon secretion, delay gastric emptying, and decrease appetite, with agonist action on its receptors, resulting in weight loss. In this context, the pharmacist's performance aimed at patients suffering from obesity disorder includes, in addition to evaluating the treatment and guiding the patient, to promote and introduce healthy lifestyle habits. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-05-29 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/30134 10.33448/rsd-v11i7.30134 |
url |
https://rsdjournal.org/index.php/rsd/article/view/30134 |
identifier_str_mv |
10.33448/rsd-v11i7.30134 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/30134/26001 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 7; e41011730134 Research, Society and Development; Vol. 11 Núm. 7; e41011730134 Research, Society and Development; v. 11 n. 7; e41011730134 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052827245215744 |